The U.S. Food and Drug Administration gave the nod for a new monoclonal antibody treatment that works against the Omicron variant. The emergency use authorization for bebtelovimab is for the treatment of mild to moderate COVID-19 in adults and pediatric patients at least 12 years of age who are at high risk for severe disease. […]
